Biogen Idec Inc (BIIB) 431.62 $BIIB
Teva, Horizon Snap Up Orphan-Disease Drugs
at Investor's Business Daily - Mon Mar 30, 10:12AM CDT
Drugmakers showed their appetite for orphan-disease drugs Monday, with two billion-dollar-plus deals sending stocks soaring. Israeli drug giant Teva Pharmaceutical Industries (TEVA) agreed to pay $101 a share in cash for Auspex Pharmaceuticals...
BIIB: 431.62 (+1.75), ESRX: 85.40 (+3.02), HZNP: 25.77 (+3.96), CVS: 103.83 (+1.33), ASPX: 100.36 (+29.45), TEVA: 62.52 (+0.54), HPTX: 45.98 (+3.24)
Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), HD: 114.63 (+0.77), RYL: 48.91 (+0.73), ALTR: 42.82 (-1.57), AMGN: 164.30 (+1.71), XOM: 85.63 (+2.05), INTC: 31.46 (-0.54), CELG: 120.02 (+1.34), LEN: 51.49 (+1.06), CVX: 106.90 (+2.62), TOL: 39.21 (-0.01), REGN: 459.78 (+5.28)
Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), KITE: 59.98 (+0.20), ONVO: 3.37 (-0.29), BIOC: 2.34 (+0.21)
European regulator validates Biogen's marketing application for Remicade biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:00AM CDT
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), AMGN: 164.30 (+1.71)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 431.62 (+1.75), GE: 25.12 (+0.26), PCYC: 256.43 (-0.12), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), HON: 104.91 (+1.95), KRFT: 90.61 (+1.51), INTC: 31.46 (-0.54), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), KMX: 69.22 (+2.53), JACK: 97.04 (+0.73), YHOO: 44.95 (-0.15), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), ABBV: 58.24 (+0.59), REGN: 459.78 (+5.28), UNP: 110.09 (+1.65), DK: 39.91 (+1.71), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), AMGN: 164.30 (+1.71), NXPI: 102.43 (+2.51), BA: 152.70 (+3.85), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), HAIN: 64.28 (+0.49), WWAV: 44.64 (-0.59), ZOES: 32.92 (+0.50), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), CNI: 66.23 (+0.08), NDLS: 17.54 (-0.06), MCD: 97.88 (+0.92), AVGO: 130.55 (+2.34)
Research and Markets: Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
Business Wire - Mon Mar 30, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l42g9r/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering.
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75)
Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
M2 - Mon Mar 30, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d4nggb/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering. The analysts forecast the Global CD market to grow at a CAGR of 2.84% over the period 2014-2019. CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties. This report covers the present scenario and the growth prospects of the Global CD market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators. An increase in strategic collaborations is one key trend being witnessed in the market. As a result of intense competition in the market, vendors are forming strategic alliances to increase their share in the market. According to the report, the high prevalence of CD has led to an increase in the number of medical prescriptions to treat the disease. Globally, the incidence rate for CD varied from 0.30 to 16.50 cases per 100,000 people annually. Further, the report states that the expiry of patents results in the loss of exclusivity leading to a rapid decline in the sales of that specific drug in the market. The expiry of patents of major drugs leads to the development of their generic forms resulting in a fragmented market. Key Vendors - AbbVie - Astra Zeneca - Biogen Idec - Johnson & Johnson - Takeda Pharmaceutical - UCB Other Prominent Vendors - Amgen - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - CD Pipeline Landscape - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/d4...bal_crohns
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), NVO: 54.68 (+0.84), MRK: 58.34 (+0.59), AMGN: 164.30 (+1.71), NVS: 101.31 (+0.91)
Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab
Business Wire - Mon Mar 30, 1:00AM CDT
Biogen (NASDAQ: BIIB) today announced the Marketing Authorization Application (MAA) for SB2, its biosimilar infliximab candidate using Remicade(R)1 as the reference product, has been validated for review by the European Medicines Agency (EMA). The MAA was submitted by the company's joint venture (JV) partner, Samsung Bioepis. This is the second MAA validated for review by the EMA as part of the joint venture. The first, SB4, a biosimilar etanercept candidate referencing Enbrel(R)2 , was validated for review earlier this year.
BIIB: 431.62 (+1.75)
Based on This Study, an Alzheimer's Disease Cure Could Be Around the Corner
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 29, 8:19AM CDT
Source: Alzheimer's Society, Facebook. While heart disease and cancer may be this nation's top two killers, it doesn't make the prospect of developing Alzheimer's any less terrifying. Based on statistics from the Alzheimer's Association, more...
BIIB: 431.62 (+1.75)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), ESRX: 85.40 (+3.02), GILD: 100.69 (-0.31), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 27, 6:59PM CDT
Cramer will look for any inkling of growth when industrial stocks report earnings next week.
GD: 137.51 (+2.47), BIIB: 431.62 (+1.75), F: 16.16 (+0.18), LMT: 204.89 (+2.66), SHAK: 49.62 (+0.62), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), RTN: 110.99 (+1.06), NOC: 162.68 (+2.20), GMCR: 113.96 (+0.76), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), JACK: 97.04 (+0.73), KMX: 69.22 (+2.53), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), REGN: 459.78 (+5.28), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), NXPI: 102.43 (+2.51), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), CELG: 120.02 (+1.34), MS: 36.31 (+0.48), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), GILD: 100.69 (-0.31), NDLS: 17.54 (-0.06), GM: 37.68 (+0.37), MCD: 97.88 (+0.92), DOW: 48.68 (+0.92), AVGO: 130.55 (+2.34), LLL: 126.69 (+1.46)
Time To Load Up On Biogen?
Valuentum - at Seeking Alpha - Fri Mar 27, 3:43PM CDT
BIIB: 431.62 (+1.75)
Stocks Finish Lower for the Week as Fed Talk Spooks Investors
at The Street - Fri Mar 27, 3:20PM CDT
Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), MON: 113.38 (+0.65), IBB: 351.32 (+3.86), SOXX: 95.09 (+1.20), NXPI: 102.43 (+2.51), KMX: 69.22 (+2.53), AYI: 172.57 (+4.57), AA: 12.96 (+0.26), TXN: 58.00 (+1.24), ADI: 64.81 (+5.97), ALXN: 180.26 (-0.33), AVGO: 130.55 (+2.34), REGN: 459.78 (+5.28)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 73.47 (+3.16), BIIB: 431.62 (+1.75), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), HUM: 181.18 (+3.66), MEIP: 1.75 (+0.01), DVA: 82.17 (+0.34), PFS: 18.69 (+0.28), GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), CLLS: 35.15 (+0.15), HHS: 7.84 (+0.08), OHRP: 2.81 (+0.07), THRX: 16.60 (+0.14), REGN: 459.78 (+5.28)
Stock Markets Hold Onto Slight Gains Ahead of Yellen Speech
at The Street - Fri Mar 27, 2:11PM CDT
Stocks inch higher on Friday afternoon, recovering from an earlier drop.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), GME: 37.69 (-0.67), OLN: 32.41 (+1.41), BBRY: 8.80 (-0.66), IBB: 351.32 (+3.86), HPQ: 31.57 (+0.08), YHOO: 44.95 (-0.15), ALXN: 180.26 (-0.33), DOW: 48.68 (+0.92), REGN: 459.78 (+5.28)
A Buyback Or Biotech Bubble?
Leo Kolivakis - Seeking Alpha - Fri Mar 27, 1:37PM CDT
(click to enlarge) Steven Davidoff Solomon, professor of law at the University of California, Berkeley, wrote a comment for the New York Times reports, General Motors' Stock Buyback Follows a Worrying Trend : General Motors' announcement that...
BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), XBI: 224.37 (+4.96), IBB: 351.32 (+3.86), PKW: 49.69 (+0.67), CELG: 120.02 (+1.34)
Which 4 Big Drugmakers Have Rising Estimates?
at Investor's Business Daily - Fri Mar 27, 12:16PM CDT
Drugmaker shares have been plunging this week, but the recent sell-off shouldn't necessarily be taken as an indicator that these stocks are doing poorly. Today's Screen of the Day features Leaders with Rising Estimates -- stocks with rising earnings...
LCI: 67.86 (+2.35), BIIB: 431.62 (+1.75), ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40)
Jim Cramer -- There's No Bubble in Biotech or Semiconductor Sectors
at The Street - Fri Mar 27, 10:23AM CDT
Some of Cramer's favorite companies are rising with their sectors Friday.
BIIB: 431.62 (+1.75), QRVO: 81.40 (+2.12), SWKS: 100.13 (+1.30), IBB: 351.32 (+3.86), SMH: 55.86 (+0.47), NXPI: 102.43 (+2.51), REGN: 459.78 (+5.28), AVGO: 130.55 (+2.34), CELG: 120.02 (+1.34)
Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020
M2 - Fri Mar 27, 7:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dv95g/albumin) has announced the addition of the "Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global albumin market was valued at USD 704.9 million in 2013 and is expected to reach USD 828.2 million by 2020, growing at a CAGR of 2.3% during the forecast period 2014 to 2020. Improved product stability, enhancement in protein purification technology and emerging use of recombinant albumin are some factors propelling market growth. The global albumin market is broadly categorized into type, applications and geography. Human serum albumin, bovine serum albumin and recombinant albumin altogether comprise the albumin type segment. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. Rising ethical concerns regarding cruelty toward bovine fetuses in deriving bovine serum as well as the retention of some amount of impurities in the albumin excipient has prompted researchers and manufacturers to opt for alternatives. Moreover, trend towards use of serum-free and chemically defined media could hamper the use of albumin as an excipient. Recombinant albumin is anticipated to be the fastest growing segment at a CAGR of 2.7% during the forecast period. Applications for this market include drug formulation and drug delivery, vaccines, and component of media. The drug formulation segment is expected to grow at the fastest CAGR of 2.4% during the forecast period from 2014 to 2020. Some examples of products with albumin as an excipient include Kogenate (Bayer), Avonex (Biogen Idec), Intron A (Merck) and Aralast (Baxter). CSL Behring, HiMedia Laboratories Pvt. Ltd., InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific and MedxBio Pte. Ltd. are some of the major companies operating in the global albumin market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Albumin Market Overview Chapter 4 Global Albumin Market Revenue (USD Million), by Type, 2012 - 2020 Chapter 5 Global Albumin Market Revenue (USD Million) and Volume (kg), by Application, 2012 - 2020 Chapter 6 Global Albumin Market Revenue (USD Million) & Volume (kg), by Geography, 2012 - 2020 Chapter 7 Recommendations Chapter 8 Company Profiles - CSL Behring LLC - HiMedia Laboratories - InVitria (Ventria Bioscience) - MedxBio Pte. Ltd. - Mitsubishi Tanabe Pharma - Novozymes A/S - Octapharma AG - RayBiotech, Inc. - Sigma-Aldrich Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/5dv95g/albumin
BIIB: 431.62 (+1.75), SIAL: 138.41 (+0.20), MRK: 58.34 (+0.59)
EMA validates Biogen/AbbVie MS drug regulatory submission
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 6:30AM CDT
BIIB: 431.62 (+1.75), ABBV: 58.24 (+0.59)
Teva, Horizon Snap Up Orphan-Disease Drugs
at Investor's Business Daily - Mon Mar 30, 10:12AM CDT
Drugmakers showed their appetite for orphan-disease drugs Monday, with two billion-dollar-plus deals sending stocks soaring. Israeli drug giant Teva Pharmaceutical Industries (TEVA) agreed to pay $101 a share in cash for Auspex Pharmaceuticals...
BIIB: 431.62 (+1.75), ESRX: 85.40 (+3.02), HZNP: 25.77 (+3.96), CVS: 103.83 (+1.33), ASPX: 100.36 (+29.45), TEVA: 62.52 (+0.54), HPTX: 45.98 (+3.24)
Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), HD: 114.63 (+0.77), RYL: 48.91 (+0.73), ALTR: 42.82 (-1.57), AMGN: 164.30 (+1.71), XOM: 85.63 (+2.05), INTC: 31.46 (-0.54), CELG: 120.02 (+1.34), LEN: 51.49 (+1.06), CVX: 106.90 (+2.62), TOL: 39.21 (-0.01), REGN: 459.78 (+5.28)
Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), KITE: 59.98 (+0.20), ONVO: 3.37 (-0.29), BIOC: 2.34 (+0.21)
European regulator validates Biogen's marketing application for Remicade biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:00AM CDT
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), AMGN: 164.30 (+1.71)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 431.62 (+1.75), GE: 25.12 (+0.26), PCYC: 256.43 (-0.12), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), HON: 104.91 (+1.95), KRFT: 90.61 (+1.51), INTC: 31.46 (-0.54), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), KMX: 69.22 (+2.53), JACK: 97.04 (+0.73), YHOO: 44.95 (-0.15), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), ABBV: 58.24 (+0.59), REGN: 459.78 (+5.28), UNP: 110.09 (+1.65), DK: 39.91 (+1.71), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), AMGN: 164.30 (+1.71), NXPI: 102.43 (+2.51), BA: 152.70 (+3.85), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), HAIN: 64.28 (+0.49), WWAV: 44.64 (-0.59), ZOES: 32.92 (+0.50), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), CNI: 66.23 (+0.08), NDLS: 17.54 (-0.06), MCD: 97.88 (+0.92), AVGO: 130.55 (+2.34)
Research and Markets: Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
Business Wire - Mon Mar 30, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l42g9r/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering.
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75)
Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
M2 - Mon Mar 30, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d4nggb/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering. The analysts forecast the Global CD market to grow at a CAGR of 2.84% over the period 2014-2019. CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties. This report covers the present scenario and the growth prospects of the Global CD market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators. An increase in strategic collaborations is one key trend being witnessed in the market. As a result of intense competition in the market, vendors are forming strategic alliances to increase their share in the market. According to the report, the high prevalence of CD has led to an increase in the number of medical prescriptions to treat the disease. Globally, the incidence rate for CD varied from 0.30 to 16.50 cases per 100,000 people annually. Further, the report states that the expiry of patents results in the loss of exclusivity leading to a rapid decline in the sales of that specific drug in the market. The expiry of patents of major drugs leads to the development of their generic forms resulting in a fragmented market. Key Vendors - AbbVie - Astra Zeneca - Biogen Idec - Johnson & Johnson - Takeda Pharmaceutical - UCB Other Prominent Vendors - Amgen - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - CD Pipeline Landscape - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/d4...bal_crohns
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), NVO: 54.68 (+0.84), MRK: 58.34 (+0.59), AMGN: 164.30 (+1.71), NVS: 101.31 (+0.91)
Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab
Business Wire - Mon Mar 30, 1:00AM CDT
Biogen (NASDAQ: BIIB) today announced the Marketing Authorization Application (MAA) for SB2, its biosimilar infliximab candidate using Remicade(R)1 as the reference product, has been validated for review by the European Medicines Agency (EMA). The MAA was submitted by the company's joint venture (JV) partner, Samsung Bioepis. This is the second MAA validated for review by the EMA as part of the joint venture. The first, SB4, a biosimilar etanercept candidate referencing Enbrel(R)2 , was validated for review earlier this year.
BIIB: 431.62 (+1.75)
Based on This Study, an Alzheimer's Disease Cure Could Be Around the Corner
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 29, 8:19AM CDT
Source: Alzheimer's Society, Facebook. While heart disease and cancer may be this nation's top two killers, it doesn't make the prospect of developing Alzheimer's any less terrifying. Based on statistics from the Alzheimer's Association, more...
BIIB: 431.62 (+1.75)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), ESRX: 85.40 (+3.02), GILD: 100.69 (-0.31), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 27, 6:59PM CDT
Cramer will look for any inkling of growth when industrial stocks report earnings next week.
GD: 137.51 (+2.47), BIIB: 431.62 (+1.75), F: 16.16 (+0.18), LMT: 204.89 (+2.66), SHAK: 49.62 (+0.62), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), RTN: 110.99 (+1.06), NOC: 162.68 (+2.20), GMCR: 113.96 (+0.76), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), JACK: 97.04 (+0.73), KMX: 69.22 (+2.53), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), REGN: 459.78 (+5.28), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), NXPI: 102.43 (+2.51), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), CELG: 120.02 (+1.34), MS: 36.31 (+0.48), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), GILD: 100.69 (-0.31), NDLS: 17.54 (-0.06), GM: 37.68 (+0.37), MCD: 97.88 (+0.92), DOW: 48.68 (+0.92), AVGO: 130.55 (+2.34), LLL: 126.69 (+1.46)
Time To Load Up On Biogen?
Valuentum - at Seeking Alpha - Fri Mar 27, 3:43PM CDT
BIIB: 431.62 (+1.75)
Stocks Finish Lower for the Week as Fed Talk Spooks Investors
at The Street - Fri Mar 27, 3:20PM CDT
Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), MON: 113.38 (+0.65), IBB: 351.32 (+3.86), SOXX: 95.09 (+1.20), NXPI: 102.43 (+2.51), KMX: 69.22 (+2.53), AYI: 172.57 (+4.57), AA: 12.96 (+0.26), TXN: 58.00 (+1.24), ADI: 64.81 (+5.97), ALXN: 180.26 (-0.33), AVGO: 130.55 (+2.34), REGN: 459.78 (+5.28)
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ABMD: 73.47 (+3.16), BIIB: 431.62 (+1.75), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), HUM: 181.18 (+3.66), MEIP: 1.75 (+0.01), DVA: 82.17 (+0.34), PFS: 18.69 (+0.28), GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), CLLS: 35.15 (+0.15), HHS: 7.84 (+0.08), OHRP: 2.81 (+0.07), THRX: 16.60 (+0.14), REGN: 459.78 (+5.28)
Stock Markets Hold Onto Slight Gains Ahead of Yellen Speech
at The Street - Fri Mar 27, 2:11PM CDT
Stocks inch higher on Friday afternoon, recovering from an earlier drop.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), BMRN: 129.13 (+0.35), GME: 37.69 (-0.67), OLN: 32.41 (+1.41), BBRY: 8.80 (-0.66), IBB: 351.32 (+3.86), HPQ: 31.57 (+0.08), YHOO: 44.95 (-0.15), ALXN: 180.26 (-0.33), DOW: 48.68 (+0.92), REGN: 459.78 (+5.28)
A Buyback Or Biotech Bubble?
Leo Kolivakis - Seeking Alpha - Fri Mar 27, 1:37PM CDT
(click to enlarge) Steven Davidoff Solomon, professor of law at the University of California, Berkeley, wrote a comment for the New York Times reports, General Motors' Stock Buyback Follows a Worrying Trend : General Motors' announcement that...
BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), XBI: 224.37 (+4.96), IBB: 351.32 (+3.86), PKW: 49.69 (+0.67), CELG: 120.02 (+1.34)
Which 4 Big Drugmakers Have Rising Estimates?
at Investor's Business Daily - Fri Mar 27, 12:16PM CDT
Drugmaker shares have been plunging this week, but the recent sell-off shouldn't necessarily be taken as an indicator that these stocks are doing poorly. Today's Screen of the Day features Leaders with Rising Estimates -- stocks with rising earnings...
LCI: 67.86 (+2.35), BIIB: 431.62 (+1.75), ACT: 304.76 (+1.20), AKRX: 48.08 (-0.40)
Jim Cramer -- There's No Bubble in Biotech or Semiconductor Sectors
at The Street - Fri Mar 27, 10:23AM CDT
Some of Cramer's favorite companies are rising with their sectors Friday.
BIIB: 431.62 (+1.75), QRVO: 81.40 (+2.12), SWKS: 100.13 (+1.30), IBB: 351.32 (+3.86), SMH: 55.86 (+0.47), NXPI: 102.43 (+2.51), REGN: 459.78 (+5.28), AVGO: 130.55 (+2.34), CELG: 120.02 (+1.34)
Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020
M2 - Fri Mar 27, 7:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dv95g/albumin) has announced the addition of the "Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global albumin market was valued at USD 704.9 million in 2013 and is expected to reach USD 828.2 million by 2020, growing at a CAGR of 2.3% during the forecast period 2014 to 2020. Improved product stability, enhancement in protein purification technology and emerging use of recombinant albumin are some factors propelling market growth. The global albumin market is broadly categorized into type, applications and geography. Human serum albumin, bovine serum albumin and recombinant albumin altogether comprise the albumin type segment. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. Rising ethical concerns regarding cruelty toward bovine fetuses in deriving bovine serum as well as the retention of some amount of impurities in the albumin excipient has prompted researchers and manufacturers to opt for alternatives. Moreover, trend towards use of serum-free and chemically defined media could hamper the use of albumin as an excipient. Recombinant albumin is anticipated to be the fastest growing segment at a CAGR of 2.7% during the forecast period. Applications for this market include drug formulation and drug delivery, vaccines, and component of media. The drug formulation segment is expected to grow at the fastest CAGR of 2.4% during the forecast period from 2014 to 2020. Some examples of products with albumin as an excipient include Kogenate (Bayer), Avonex (Biogen Idec), Intron A (Merck) and Aralast (Baxter). CSL Behring, HiMedia Laboratories Pvt. Ltd., InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific and MedxBio Pte. Ltd. are some of the major companies operating in the global albumin market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Albumin Market Overview Chapter 4 Global Albumin Market Revenue (USD Million), by Type, 2012 - 2020 Chapter 5 Global Albumin Market Revenue (USD Million) and Volume (kg), by Application, 2012 - 2020 Chapter 6 Global Albumin Market Revenue (USD Million) & Volume (kg), by Geography, 2012 - 2020 Chapter 7 Recommendations Chapter 8 Company Profiles - CSL Behring LLC - HiMedia Laboratories - InVitria (Ventria Bioscience) - MedxBio Pte. Ltd. - Mitsubishi Tanabe Pharma - Novozymes A/S - Octapharma AG - RayBiotech, Inc. - Sigma-Aldrich Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/5dv95g/albumin
BIIB: 431.62 (+1.75), SIAL: 138.41 (+0.20), MRK: 58.34 (+0.59)
EMA validates Biogen/AbbVie MS drug regulatory submission
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 6:30AM CDT
BIIB: 431.62 (+1.75), ABBV: 58.24 (+0.59)
